Earnings Call Summary | BioLine Rx(BLRX.US) Q1 2024 Earnings Conference
Earnings Call Summary | BioLine Rx(BLRX.US) Q1 2024 Earnings Conference
The following is a summary of the BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript:
以下是BioLineRx Ltd. (BLRX) Q1 2024業績會議調 transcript 的摘要：
Financial Performance:
金融業績：
BioLineRx reported Q1 2024 revenues of $6.9 million, a significant increase from no recorded revenues in Q1 2023.
The company earned revenue from the Gloria Biosciences license agreement, milestone payment, and product sales of APHEXDA in the US.
Cost of revenues for Q1 2024 was $1.5 million, and the net loss was curbed to $0.7 million, down from $12.2 million in Q1 2023.
The firm maintained cash and equivalents of $28.2 million as of March 31, 2024.
Gross margin was reported to be well over 90%.
BioLineRx報告2024 Q1 營業收入爲690萬美元，較2023 Q1的無記錄營業收入大幅增長。
公司通過Gloria Biosciences的許可協議、里程碑付款和APHEXDA在美國的產品銷售獲得收入。
2024 Q1營業成本爲150萬美元，淨虧損抑制在70萬美元，較2023 Q1的1220萬美元有所下降。
該公司截至2024年3月31日，保持了2820萬美元的現金和等價物。
毛利率報告顯示超過90%。
Business Progress:
業務進展：
Successful commercialization of APHEXDA has been marked by establishing formulary placement in key centers across the US.
Expansion goals aim to reach 60% formulary placement by end of 2024.
In collaboration with Gloria Biosciences, a bridging study for APHEXDA approval in China is set for H2 2024.
Phase 2 trials of motixafortide in pancreatic cancer are underway in partnership with Columbia University and Regeneron.
Collaboration with Gloria Biosciences will further evaluate motixafortide in Phase 2b trials for pancreatic cancer.
Continuation of Phase 1 trial for sickle cell disease treatment at Washington University School of Medicine, with data anticipated in H2 2024.
Active collaboration dialogue with potential partners indicates future project prospects.
Noteworthy achievement of CMS pass-through status for hospital bundling displays growth in the healthcare sector.
Assurance of robust drug supply for both commercial and clinical needs provides stable future prospects.
成功的APHEXDA商業化已通過在美國關鍵中心建立處方清單來實現。
擴展目標旨在在2024年年底達到60%的處方清單位置。
與 Gloria Biosciences 合作，將在2024下半年進行APHEXDA在中國批准的橋接研究。
motixafortide在胰腺癌的二期臨床試驗正在與哥倫比亞大學和再生元合作中進行。
與 Gloria Biosciences 的合作將進一步評估 motixafortide 在胰腺癌二期臨床試驗中的表現。
華盛頓大學醫學院正在進行鐮狀細胞病治療的一期試驗，數據預計在2024下半年公佈。
與潛在合作伙伴的積極對話表明了未來的項目前景。
荷包依賴狀態的保證爲醫療保健板塊的增長展示做出了貢獻。
確保對商業和臨床需求提供強有力藥品供應，提供了穩定的未來前景。
More details: BioLine Rx IR
更多詳情：BioLine Rx IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。